A practical reference on prothymosin alpha: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
=== Elderly === Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss.
==== Ontario Student Assistance Program ==== In early 2026, the Ford government announced changes to the Ontario Student Assistance Program (OSAP) and billions in new funding for Ontario's financially struggling colleges and universities. The government announced the end of the tuition freeze for public colleges and universities, allowing them to raise fees by up to two percent per year over three years, and announced changes to OSAP funding, with grants reduced to a maximum of 25 percent for grants, and loans increased to a minimum of 75 percent; the changes saw protests from students across the province. This followed changes made to the program by the government in January 2019, which included a 10% tuition fee reduction for all programs in 2019–20, followed by a freeze in 2020–21, and the cutting of the OSAP budget from $2 billion to $1.4 billion.
=== Bleaching === About 60% of the world's production of hydrogen peroxide is used for pulp- and paper-bleaching. The second major industrial application is the manufacture of sodium percarbonate and sodium perborate, which are used as mild bleaches in laundry detergents. A representative conversion is:
Sources: en.wikipedia.org
Under its terms the Basuto would be allowed to keep their guns, provided they officially register them and pay an annual fee of one pound per weapon. The Cape pledged to provide an amnesty for the rebels and allow for Quthing to remain a part of Basutoland. The Basuto agreed to pay a collective fine of 5,000 cattle and compensate Basuto loyalists and white traders. The Award marked the end of the conflict. The Cape's casualties during the war totaled 94 killed and 112 wounded.
A low-pressure compressor is often the air supply of choice for surface-supplied diving, as it is virtually unlimited in the amount of air it can supply, provided the delivery volume and pressure are adequate for the application. A low-pressure compressor can run for tens of hours, needing only refueling, periodical filter drainage and occasional running checks, and is therefore more convenient than high-pressure storage cylinders for primary air supply. It is critical to diver safety that the compressor is suitable for breathing air delivery, uses a suitable oil, is adequately filtered, and takes in clean and uncontaminated air. Positioning of the intake opening is important, and may have to be changed if the relative wind direction changes, to ensure that no engine exhaust gas enters the intake. Various national standards for breathing air quality may apply. Power for portable compressors is usually a 4-stroke petrol (gasoline) engine. Larger, trailer mounted compressors, may be diesel powered. Permanently installed compressors on dive support boats are likely to be powered by 3-phase electric motors. The compressor should be provided with an accumulator (also known as a volume tank, receiver, or air reserve tank), and a relief valve. The accumulator functions as an additional water trap, but the main purpose is to provide a reserve volume of pressurised air. The relief valve allows any excess air to be released back to the atmosphere while retaining the appropriate supply pressure in the accumulator.
=== Remediation of DNAPLs === Mitigation of LNAPLs tends to be less complex and require simpler engineering strategies. Conversely, DNAPLs can seep into cracks in the parent material of the subsurface, complicating both their movement and the technology required for their mitigation. In a best-case scenario, the DNAPL is continuous and has collected as a reservoir above the impermeable layer. In this scenario, a recovery well can be drilled and installed. When it comes to DNAPL remediation, the earlier it is removed, the better.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.